within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR09_EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat;

model EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat
  extends Pharmacolibrary.Drugs.ATC.J.J05AR09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat</td></tr><tr><td>ATC code:</td><td>J05AR09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>This fixed-dose combination consists of emtricitabine (a nucleoside reverse transcriptase inhibitor), tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor), elvitegravir (an integrase inhibitor), and cobicistat (a pharmacokinetic enhancer/booster). The combination is used as a complete regimen for the treatment of HIV-1 infection in adults and adolescents. It is widely approved and used as a single-tablet regimen to improve adherence and reduce pill burden in HIV therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters have been reported in healthy adult subjects after oral administration of the fixed-dose combination tablet (once daily). PK parameters reflect values at steady-state.</p><h4>References</h4><ol><li><p>Ogbuagu, O (2016). Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. <i>Expert review of anti-infective therapy</i> 14(12) 1113–1126. DOI:<a href=\"https://doi.org/10.1080/14787210.2016.1255551\">10.1080/14787210.2016.1255551</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27797606/\">https://pubmed.ncbi.nlm.nih.gov/27797606</a></p></li><li><p>Yamada, H, et al., &amp; Irie, S (2018). Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. <i>Clinical pharmacology in drug development</i> 7(2) 132–142. DOI:<a href=\"https://doi.org/10.1002/cpdd.365\">10.1002/cpdd.365</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28581645/\">https://pubmed.ncbi.nlm.nih.gov/28581645</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end EmtricitabineTenofovirDisoproxilElvitegravirAndCobicistat;
